Kun Kim

4PUBLICATIONS
2CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 21, 2026
The application of excess hazard models for plausible long-term extrapolation in cost-effectiveness: a re-evaluation of immunotherapy in advanced non-small cell lung cancer using the KEYNOTE-024 trial.

|Oct 27, 2025
Cost of treatment of metastatic non-small lung cancer in Sweden, 2011-2023.

Kun Kim, Michael Sweeting, Nils Wilking

|Jan 14, 2025
Long-Term Real-World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score-Matched Analysis.

Kun Kim, Michael Sweeting, Linus Jönsson

|Sep 12, 2024
General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden.

Kun Kim, Michael Sweeting, Nils Wilking

Pageof 1

Frequent Collaborators

2 joint publications

Michael Sweeting

1 joint publications

Linus Mattias Jönsson